Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | G6PD | P11413 | 1/20 | 0.36 |
| ▸ | IDE | P14735 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PNMT | P11086 | 2/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.32 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28464838 | 0.80 | PSIP1 (0.42) | SMN1; SMN2ALDH1A1PNMT | |
| SCHEMBL7048593 | 0.79 | ALDH1A1 (0.39) | SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL1448262 | 0.77 | SMN1; SMN2 (0.37) | G6PDIDESMN1; SMN2ENPP2LMNA | |
| SCHEMBL941266 | 0.77 | G6PD (0.37) | G6PDIDESMN1; SMN2ENPP2LMNA | |
| SCHEMBL971270 | 0.75 | LMNA (0.42) | G6PDIDESMN1; SMN2ENPP2LMNA | |
| SCHEMBL5136162 | 0.75 | ENPP2 (0.45) | G6PDIDESMN1; SMN2ENPP2LMNA | |
| SCHEMBL1447811 | 0.75 | PTGS2 (0.38) | G6PDIDESMN1; SMN2ENPP2LMNA | |
| SCHEMBL635411 | 0.75 | G6PD (0.44) | G6PDIDESMN1; SMN2ENPP2LMNA | |
| SCHEMBL10479008 | 0.75 | NPC1 (0.40) | SMN1; SMN2LMNAALDH1A1MAPTEPAS1 | |
| SCHEMBL1459816 | 0.72 | KIF11 (0.40) | G6PDIDESMN1; SMN2ENPP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109415359-B | Heterocyclic GPR119 agonist compounds | 人类制药有限公司 | 2022-03-04 | — | — | CN | disclosed |
| US-10954229-B2 | GPR119 agonist compounds | MANKIND PHARMA LTD. (IN) | 2021-03-23 | — | — | US | disclosed |
| US-20200317661-A1 | NOVEL GPR119 AGONIST COMPOUNDS | MANKIND PHARMA LTD. (IN) | 2020-10-08 | — | — | US | disclosed |
| US-10752622-B2 | GPR119 agonist compounds | MANKIND PHARMA LTD. (IN) | 2020-08-25 | — | — | US | disclosed |
| US-20190127363-A1 | NOVEL GPR119 AGONIST COMPOUNDS | MANKIND PHARMA LTD. (IN) | 2019-05-02 | — | — | US | disclosed |
| US-10208030-B2 | GPR119 agonist compounds | MANKIND PHARMA LTD. (IN) | 2019-02-19 | — | — | US | disclosed |
| US-20170291894-A1 | NOVEL GPR119 AGONIST COMPOUNDS | MANKIND PHARMA LTD. (IN) | 2017-10-12 | — | — | US | disclosed |
| EP-3004053-A2 | A PROCESS FOR PREPARATION OF PYRROLES HAVING HYPOLIPIDEMIC HYPOCHOLESTEREMIC ACTIVITIES | Cadila Healthcare Limited (IN) | 2016-04-13 | — | — | EP | disclosed |
| US-9115114-B2 | Bromodomain inhibitors | Quanticel Pharmaceuticals, Inc. (US) | 2015-08-25 | — | — | US | disclosed |
| WO-2015033357-A2 | AN IMPROVED PROCESS FOR THE PREPARATION OF PYRROLE DERIVATIVES | CADILA HEALTHCARE LIMITED (IN) | 2015-03-12 | — | — | WO | disclosed |
| EP-0904269-A1 | 3,4-DIARYL-2-HYDROXY-2,5-DIHYDROFURANS AS PRODRUGS TO COX-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1999-03-31 | — | — | EP | disclosed |
| EP-0882016-A1 | ALKYLATED STYRENES AS PRODRUGS TO COX-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1998-12-09 | — | — | EP | disclosed |
| EP-0863891-A1 | (METHYLSULFONYL)PHENYL-2-(5H)-FURANONES AS COX-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1998-09-16 | — | — | EP | disclosed |
| US-5789413-A | ANTIINFLAMMATORY AGENT | MERCK FROSST CANADA, INC. (CA) | 1998-08-04 | — | — | US | disclosed |
| US-5698584-A | NON-STEROIDAL ANTIINFLAMMATORY AGENTS | MERCK FROSST CANADA, INC. (CA) | 1997-12-16 | — | — | US | disclosed |
| WO-1997028121-A1 | ALKYLATED STYRENES AS PRODRUGS TO COX-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1997-08-07 | — | — | WO | disclosed |
| EP-0783486-A1 | NOVEL PROSTAGLANDIN SYNTHASE INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-07-16 | — | — | EP | disclosed |
| WO-1997016435-A1 | 3,4-DIARYL-2-HYDROXY-2,5-DIHYDROFURANS AS PRODRUGS TO COX-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1997-05-09 | — | — | WO | disclosed |
| WO-1997014691-A1 | (METHYLSULFONYL)PHENYL-2-(5H)-FURANONES AS COX-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1997-04-24 | — | — | WO | disclosed |
| CN-1143365-A | Phenyl-heterocycles as COX-2 inhibitors | MERCK FROSST CANADA INC (CA) | 1997-02-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200317661-A1 | NOVEL GPR119 AGONIST COMPOUNDS | GPR119, GPR84, GPR88 | G6PD 4704/4885IDE 4283/4885SMN1; SMN2 2548/4885 |
| US-20170291894-A1 | NOVEL GPR119 AGONIST COMPOUNDS | GPR119, GPR84, GPR88 | G6PD 4704/4885IDE 4283/4885SMN1; SMN2 2548/4885 |
| US-10752622-B2 | GPR119 agonist compounds | GPR119, GPR84, GPR65 | G6PD 4359/4885IDE 4166/4885SMN1; SMN2 2380/4885 |
| US-10954229-B2 | GPR119 agonist compounds | GPR119, GPR84, GPR65 | G6PD 4359/4885IDE 4166/4885SMN1; SMN2 2380/4885 |
| US-10208030-B2 | GPR119 agonist compounds | GPR119, GPR84, GPR65 | G6PD 4359/4885IDE 4166/4885SMN1; SMN2 2380/4885 |
| US-20190127363-A1 | NOVEL GPR119 AGONIST COMPOUNDS | GPR119, GPR84, GPR88 | G6PD 4704/4885IDE 4283/4885SMN1; SMN2 2548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.